UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015810
Receipt number R000018394
Scientific Title The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration.
Date of disclosure of the study information 2015/01/01
Last modified on 2019/03/28 16:23:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration.

Acronym

The change of retinal sensitivity with IVA for AMD

Scientific Title

The change of retinal sensitivity with intravitreal injection of aflibercept for wet type of age-related macular degeneration.

Scientific Title:Acronym

The change of retinal sensitivity with IVA for AMD

Region

Japan


Condition

Condition

wet type age-related macular degeneration

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the visual function from various angle with the analysis of retinal sensitivity after intravitreal injection of aflibercept for wet type of age-related macular degeneration.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The change amount of retinal sensitivity at six month from base line after initial therapy of intravitreal injection of aflibercept for wet type of age-related macular degeneration

Key secondary outcomes

1.The ratio of patients with improvement or preservation of visual acuity after intravitreal injection of aflibercept

2.The change amount of visual aquity at 1,3,6,12 months from base line

3.The change amount of central foveal thickness at 1,3,6,12 months from base line

4.The ratio of patients with subretinal or intraretinal exdative change at 6 and 12 months

5.The change amount of retinal sensitivity at 1,3 and 12 months from base line


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)patients who received informed consent and agreed the investigation

2)man or woman 50 years or older

3)patiens with typical AMD or polypoidal chorodal vasculopathy

4)treatment naive for AMD

5)decimal visual acuity within 0.1 to 1.2

Key exclusion criteria

1.Patients who need to undergo intravitreal injection of aflibercept for their both eyes.
2.The lesion is more than 12 disc diameter area with fluorecein angiography
3.Subretinal hemorrhage with 50 percent or more of the lesion area
4.Subretinal scar or fibrosis with 50 percent or more of the lesion area
5.retinal pigment epithelium tear
6.patients who had past stage 3 or 4 macular hole
7.patients who received the therapy with triamcinolone acetonide within 6 months
8.patients who received the therapy with Dexamethasone within 30 days
9.patients who received intra occular surgery within 6 months
10.patients who received pars plana vitrectomy or submacular surgery
11.patinets with intra or external occular infection or inflamation
12.patients with uveitis in any eye
13.fluorescein or indocianine green alergy
14.pregnancy or possibility of pregnancy or woman who are lactating
15.patient who are judged unsuitable for the investigation by the doctor

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Yamamoto

Organization

Chiba University Graduate School of Medicine

Division name

Department of Ophthalmology and Visual Science

Zip code


Address

1-8-1 Inohana,Chuo-ku,Chiba 2608670,Japan

TEL

043-222-7171

Email

shuyama@faculty.chiba-u.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masayasu Kitahashi

Organization

Chiba University Graduate School of Medicine

Division name

Department of Ophthalmology and Visual Science

Zip code


Address

1-8-1 Inohana,Chuo-ku,Chiba 2608670,Japan

TEL

043-222-7171

Homepage URL


Email

kitahashi@faculty.chiba-u.jp


Sponsor or person

Institute

Department of Ophthalmology and Visual Science
Chiba University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Ophthalmology and Visual Science
Chiba University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千葉大学医学部附属病院眼科(千葉県)


Other administrative information

Date of disclosure of the study information

2015 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 09 Month 01 Day

Date of IRB

2016 Year 08 Month 31 Day

Anticipated trial start date

2016 Year 10 Month 01 Day

Last follow-up date

2019 Year 03 Month 09 Day

Date of closure to data entry

2019 Year 03 Month 09 Day

Date trial data considered complete

2019 Year 03 Month 11 Day

Date analysis concluded

2019 Year 03 Month 14 Day


Other

Other related information

prospective observentional study


Management information

Registered date

2014 Year 12 Month 01 Day

Last modified on

2019 Year 03 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018394


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name